uniQure Posts Q3 Loss of $61.2M, $768.4M Cash Funds Operations Into 2030
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure reported a $61.2 million Q3 net loss and $768.4 million in cash, enough to fund operations into 2030, while detailing the confirmatory trial design for AMT-130 ahead of a May 1, 2027 PDUFA date.
Key Events · Earnings and Guidance · QURE
-
Q3 Net Loss Narrows to $61.2M
Net loss was $61.2 million, or $0.88 per share, versus $80.5 million, or $1.38 per share, in Q3 2025. Revenue rose to $5.2 million from $3.7 million.
-
Cash of $768.4M Funds Operations Into 2030
Cash, cash equivalents and investment securities totaled $768.4 million at September 30, 2026, up from $622.5 million at December 31, 2025, funding projected operating expenses into 2030.
-
Confirmatory Study Design Aligned With FDA
Randomized, standard-of-care-controlled trial of approximately 200 patients in a 2:1 ratio, with TFC as the primary endpoint at 36 months; U.S. patient screening expected to begin by the end of 2026.
-
PDUFA Date Set for May 1, 2027
The AMT-130 BLA for Huntington's disease is under Priority Review with a PDUFA target action date of May 1, 2027, following FDA acceptance disclosed on 2026-11-02.
Analysis · QURE · Life Sciences
For a pre-commercial gene therapy company, the quarterly numbers themselves are unremarkable: revenue of $5.2 million against R&D of $35.5 million and SG&A of $23.9 million. The balance sheet is what matters. Cash and investments stood at $768.4 million, up from $622.5 million at year-end 2025, and management says that funds operations into 2030. That removes any near-term financing need ahead of the May 1, 2027 PDUFA date for AMT-130 in Huntington's disease, keeping the story on the FDA decision rather than on dilution. The release also adds detail the 2026-11-02 8-K did not carry: the confirmatory study is designed as a ~200-patient, 2:1 randomized trial against standard of care with TFC as the primary endpoint at 36 months, and U.S. patient screening is expected to begin by the end of 2026.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $22.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $8.73 to $51.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.